Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MedAdvisor (MDR) has extended its health program deal with U.S. pharmaceutical company Adheris for another three months
  • A US$3.4 million (roughly A$4.4 million) deal was inked in December last year and had a five-month term
  • Pleasingly, the extension is for a shorter term but has a greater value of US$4.7 million (roughly A$6.19 million)
  • The health programs deliver personalised content to the right patients to make them aware of the benefits of certain medication vaccines
  • MedAdvisor ended the day up 6.15 per cent with shares closing at 34.5 cents

MedAdvisor (MDR) has reported U.S. pharmaceutical company Adheris has extended its health program deal for about three months.

This deal is an extension to the five-month agreement announced in December last year.

The original deal was valued at US$3.4 million (roughly A$4.4 million), whereas the extension deal has an estimated value of US$4.7 million (roughly A$6.19 million).

“We’re delighted to have another health program extended in the U.S. market,” MedAdvisor CEO and Managing Director Robert Read said.

“These health programs deliver tailored content specifically to the right patients based on advanced algorithms and are designed to ensure they are aware of the benefits of certain medications vaccines,” he added.

MedAdvisor’s technology platform allows user to connect to their local pharmacy and automatically keep up to date with prescriptions, medication doses, and doctors appointments.

Under the deal, Adheris is offering its network of 25,000 pharmacies with an opt-out population of about 180 million patients to deliver direct mail to patients at the right time. According to the company, The deal complements MedAdvisor’s existing offering, which ensures patients stay on top of their health.

MedAdvisor ended the day up 6.15 per cent with shares closing at 34.5 cents.

MDR by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug